Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 17Completed 7Unknown 3Not yet recruiting 3Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × alectinib × Clear all
NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Massachusetts General Hospital

Phase 1/2 Terminated
11 enrolled 21 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Dana-Farber Cancer Institute

Phase 1/2 Terminated
5 enrolled 8 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡